Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

16.7%

5 terminated/withdrawn out of 30 trials

Success Rate

80.8%

-5.7% vs industry average

Late-Stage Pipeline

17%

5 trials in Phase 3/4

Results Transparency

100%

21 of 21 completed trials have results

Key Signals

4 recruiting21 with results

Enrollment Performance

Analytics

Phase 2

16(61.5%)

Phase 3

5(19.2%)

Phase 1

3(11.5%)

N/A

2(7.7%)

26Total

Phase 2(16)

Phase 3(5)

Phase 1(3)

N/A(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (30)

Showing 20 of 30 trials

NCT05751941Phase 2Recruiting

Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer

Role: collaborator

NCT05806814Phase 1Recruiting

Sipuleucel-T Based Autologous Cellular Immunotherapy for Advanced Prostate Cancer

Role: collaborator

NCT06100705Phase 2Recruiting

Sipuleucel-T Combined With Bipolar Androgen Therapy in Men With mCRPC

Role: collaborator

NCT06134232Phase 2Recruiting

Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T

Role: lead

NCT03686683Phase 3Completed

Open- Label Trial of Sipuleucel-T Administered to Active Surveillance Patients for Newly Diagnosed Prostate Cancer

Role: lead

NCT00849290Phase 2Completed

Immunotherapy For Men With Objective Disease Progression On Protocol D9902 Part B (NCT00065442)

Role: lead

NCT01804465Phase 2Completed

Sipuleucel-T With Immediate vs. Delayed Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Blockade for Prostate Cancer

Role: collaborator

NCT01833208Not ApplicableCompleted

Radiation Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Receiving Sipuleucel-T

Role: collaborator

NCT02463799Phase 2Completed

Study of Sipuleucel-T W/ or W/O Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-MCRPC

Role: collaborator

NCT01706458Phase 2Completed

Provenge With or Without pTVG-HP DNA Booster Vaccine in Prostate Cancer

Role: collaborator

NCT03024216Phase 1Completed

Clinical Study of Atezolizumab (Anti-PD-L1) and Sipuleucel-T in Patients With Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate Cancer

Role: collaborator

NCT01981109Terminated

Positive Imaging Study for Distant Metastases in Patients With Castration-Resistant Prostate Cancer

Role: lead

NCT01727154Terminated

Immune Monitoring Protocol in Men With Prostate Cancer Enrolled in a Clinical Trial of Sipuleucel-T

Role: lead

NCT01306890Completed

A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer

Role: lead

NCT01487863Phase 2Completed

Concurrent vs. Sequential Sipuleucel-T & Abiraterone Treatment in Men With Metastatic Castrate Resistant Prostate Cancer

Role: lead

NCT02232230Completed

A Multicenter Trial Enrolling Men With Advanced Prostate Cancer Who Are to Receive Combination Radiation and Sipuleucel-T

Role: collaborator

NCT01981122Phase 2Completed

A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer

Role: lead

NCT00779402Phase 3Completed

PROvenge Treatment and Early Cancer Treatment

Role: lead

NCT02042053Not ApplicableTerminated

PET/MR Assessment of Sipuleucel T Treatment for Metastatic Castration Resistant Prostate Cancer

Role: collaborator

NCT01338012Phase 2Terminated

Sipuleucel-T in Metastatic Castrate Resistant Prostate Cancer

Role: lead